SCHEMBL6887388

SCHEMBL6887388

Cc1ccc(CN2C3CCCC2CC(Nc2ccccc2Br)C3)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3E A5X5Y0 1/20 0.63
HTR3B O95264 1/20 0.63
CHRM4 P08173 1/20 0.63
CHRM5 P08912 1/20 0.63
CHRNB2 P17787 1/20 0.63
CHRNB4 P30926 1/20 0.63
CHRNA3 P32297 1/20 0.63
HRH1 P35367 1/20 0.63
CHRNA7 P36544 1/20 0.63
CHRNA4 P43681 1/20 0.63
HTR3A P46098 1/20 0.63
TMEM97 Q5BJF2 1/20 0.63
HTR3D Q70Z44 1/20 0.63
HTR3C Q8WXA8 1/20 0.63
SIGMAR1 Q99720 1/20 0.63
OPRK1 P41145 5/20 0.55
ALPL P05186 2/20 0.54
ALDH1A1 P00352 1/20 0.54
PLA2G1B P04054 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2190458 0.90 SIGMAR1 (0.62) HTR3EHTR3BCHRM4CHRM5CHRNB2
SCHEMBL6886979 0.90 SIGMAR1 (0.62) HTR3EHTR3BCHRM4CHRM5CHRNB2
SCHEMBL6886806 0.90 SIGMAR1 (0.65) HTR3EHTR3BCHRM4CHRM5CHRNB2
SCHEMBL2189011 0.87 L3MBTL1 (0.60) HTR3EHTR3BCHRM4CHRM5CHRNB2
SCHEMBL6885993 0.87 SIGMAR1 (0.59) HTR3EHTR3BCHRM4CHRM5CHRNB2
SCHEMBL12463006 0.87 L3MBTL1 (0.60) HTR3EHTR3BCHRM4CHRM5CHRNB2
SCHEMBL6887464 0.83 SIGMAR1 (0.57) HTR3EHTR3BCHRM4CHRM5CHRNB2
SCHEMBL6885989 0.82 SIGMAR1 (0.72) HTR3EHTR3BCHRM4CHRM5CHRNB2
SCHEMBL6889532 0.80 CXCR6 (0.57) HTR3EHTR3BCHRM4CHRM5CHRNB2
SCHEMBL6886856 0.80 SIGMAR1 (0.53) HTR3EHTR3BCHRM4CHRM5CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170224665-A1 SELECTIVE HIGH AFFINITY ALFA3BETA4 NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS Astraea Therapeutics (US) 2017-08-10 US disclosed
US-9670198-B2 Nicotinic acetylcholine receptor modulators ASTRAEA THERAPEUTICS, LLC (US) 2017-06-06 US disclosed
US-9062042-B2 Nicotinic acetylcholine receptor modulators ASTRAEA THERAPEUTICS, LLC (US) 2015-06-23 US disclosed
US-20150148541-A1 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS Astraea Therapeutics (US) 2015-05-28 US disclosed
US-20110172264-A1 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS ASTRAEA THERAPEUTICS, LLC 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172264-A1 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS CHRNA4, CHRNA3, CHRNA6 HTR3E 139/4885HTR3B 81/4885CHRM4 17/4885
US-20170224665-A1 SELECTIVE HIGH AFFINITY ALFA3BETA4 NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS CHRNA3, CHRNA4, CHRNB3 HTR3E 181/4885HTR3B 56/4885CHRM4 19/4885
US-20150148541-A1 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS CHRNA3, CHRNA4, CHRNA2 HTR3E 172/4885HTR3B 73/4885CHRM4 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.